Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$59.53T
24h Vol:
$11.13B
Dominance:
MSFT:5.18%
Stocklytics Platform
BETA
Instrument logo  REGN

Regeneron Pharmaceuticals Inc

REGN
68 / 100
S&P500
$971.19arrow_drop_down-1.18%-$11.63
Key Stats
Open$967.50
Prev. Close$966.09
EPS34.79
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$106.08B
PE Ratio28.25
LOWHIGH
Day Range966.09
988.13
52 Week Range684.81
998.33
Ratios
P/B Ratio4.15
Revenue$13.11B
Operating M. %29.20%
Earnings$3.95B
Earnings Growth %-8.87%
EBITDA Margin %35.48%
ROE %16.26%
EPS34.79
Fundamentals
RPS$122.94
Gross Profit$12.23B
EBITDA$5.13B
Total Debt$2.70B
P/S Ratio8.2x
Enterprise to EBITDA21.25
Profit Margin30.14%
ROA8.49%
Debt/Equity Ratio0.10%
Payout Ratio-
Industry average yield3.00%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

REGNarrow_drop_up1.73%
US Healthcare Sectorarrow_drop_up1.34%
US Marketarrow_drop_up0.03%
REGN / Market
REGN exceeded the US Market which returned 0.03% over the last twenty four hours.
REGN / Healthcare Sector
REGN exceeded the US Healthcare sector which returned 1.34% over the last twenty four hours.

Regeneron Pharmaceuticals Inc (REGN) Statistics

Regeneron Pharmaceuticals Inc (REGN) is a leading biotechnology company that focuses on the discovery, development, and commercialization of innovative medicines for serious diseases. The company's stock statistics demonstrate its strong performance in the market. Over the past year, REGN stock has shown impressive growth, outpacing the overall sector. Its valuation metrics also indicate its solid market position and potential for future growth. With a high price-to-earnings ratio and strong revenue growth, REGN is considered a valuable investment opportunity. Moreover, its fundamentals, such as its strong pipeline of drugs and robust financial position, further support its positive outlook.

REGN's stock performance has consistently outperformed its sector, reflecting the company's strong market position and investor confidence. The stock's revenue per share has also been impressive, demonstrating the company's ability to generate substantial revenue from its products. Moreover, REGN's Enterprise to EBITDA ratio, a measure of its profitability, is favorable, indicating efficient operations and solid financial performance. Furthermore, the company's profit margin is noteworthy, reflecting its ability to generate profit from its sales. While REGN does have a significant amount of total debt, its strong gross profit suggests that the company has the ability to manage and repay its debt obligations.

add Regeneron Pharmaceuticals Inc to watchlist

Keep an eye on Regeneron Pharmaceuticals Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
How much debt does Regeneron Pharmaceuticals Inc (REGN) have?

Regeneron Pharmaceuticals Inc (REGN) has a total debt of $2.7B. The net debt, which accounts for cash and cash equivalents against the total debt, is -$27.1M.

question_mark
How has Regeneron Pharmaceuticals Inc (REGN) stock's performance compared to its sector and the market over the past year?

Over the past year, Regeneron Pharmaceuticals Inc (REGN) has experienced a price change of 26.05%. Compared to the Healthcare sector, which saw a change of 30.80%, Regeneron Pharmaceuticals Inc has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 36.77%, it has fallen short of the market average. This comparison highlights Regeneron Pharmaceuticals Inc's performance relative to both its sector and the overall market over the last year.

question_mark
What is the PE ratio of Regeneron Pharmaceuticals Inc (REGN) stock?

The PE (Price to Earnings) ratio of Regeneron Pharmaceuticals Inc (REGN) is currently 28.25. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.

question_mark
What is the EPS of Regeneron Pharmaceuticals Inc (REGN) stock?

The Earnings Per Share (EPS) for Regeneron Pharmaceuticals Inc (REGN), calculated on a diluted basis, is $34.79. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

question_mark
What is the operating margin of Regeneron Pharmaceuticals Inc (REGN) stock?

The operating margin for Regeneron Pharmaceuticals Inc (REGN) is 29.2%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

question_mark
What is the EBITDA of Regeneron Pharmaceuticals Inc (REGN) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Regeneron Pharmaceuticals Inc (REGN) is $5.13B. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.